Priority Lists
Protocol Posting of
Activations
A Phase II/III Randomized Trial of Two Doses (Phase III-Standard vs. High) and Two High Doe Schedules (Phase II-Once vs. Twice Daily) for Delivering Prophylactic Cranial Irradiation for Patients with Limited Disease Small Cell Lung Cancer
| Study Coordinator(s) | Zelanna Goldberg, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists |
"A Phase II Trial of Gemcitabine, Carboplatin and PS-341 (NSC-681239) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)."
| Study Coordinator(s) | Angela M. Davies, M.D., Primo N. Lara, Jr., M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Closures
Permanent Closure Effective 2/15/04
A Phase II Trial of a D1/3-MAGE-3-His Fusion Protein (NSC-719274) with Adjuvant SB-AS02B (NSC-719275) for Patients with Selected Stage IV, M1a or M1b Metastatic Melanoma
| Study Coordinator(s) | Jeffrey S. Weber, M.D., Vernon K. Sondak, M.D., Mary L. Disis, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
| Closure Date | 2004-02-15 |
Amendments, Revisions, Memoranda
Amendment #2
A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients with "No Evidence of Disease" after Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma
| Action Codes | IP, AC, ER |
| Study Coordinator(s) | Kim A. Margolin, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists |
Memorandum
A Randomized Phase III Equivalence Trial of Irinotecan (CPT-11) Versus Oxaliplatin (OXAL)/5-Fluorouracil (5-FU)/Leucovorin (CF) in Patients with Advanced Colorectal Carcinoma Previously Treated with 5-FU
| Study Coordinator(s) | Philip A. Philip, M.D.,Ph.D. |
| Participants | Members, Surgeons, NCORP |
Revision #6
A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma
| Study Coordinator(s) | Deborah T. Blumenthal, M.D., Alexander M. Spence, M.D., Keith J. Stelzer, M.D.,Ph.D., Andrew Edward Sloan, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, Radiation Oncologists |
Revision #2
A Phase III Randomized Study of Pegylated Liposomal Doxorubicin Plus Carboplatin Versus Carboplatin in Platinum-Sensitive Patients with Recurrent Epithelial Ovarian or Peritoneal Carcinoma after Failure of Initial Platinum-Based Chemotherapy
| Study Coordinator(s) | Ana Maria Lopez, M.D., M.Ph, Sharon Wilczynski, M.D.,Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, CTSU Institutions in the United States |
Revision #2
A Phase I Pharmacokinetic Study of Epothilone B Analogue BMS-247550 (NSC-710428D) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.
| Study Coordinator(s) | Angela M. Davies, M.D., Timothy W. Synold, Pharm. D., Chris Takimoto, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Amendment #6
Lung Cancer Specimen Repository Protocol, Ancillary
| Action Codes | FBR |
| Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Memorandum
A Phase III Study of Adjuvant Ganglioside Vaccination GM2- KLM/QS-21 Therapy vs. High-Dose Interferon Alpha-2b (Intron A) for High Risk Melanoma (T4>4 mm Primary or Regional Lymph Node Metastasis)
| Study Coordinator(s) | Jeffrey A. Sosman, M.D. |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required